|
1
|
Ottaviani G and Jaffe N: Epidemiology of
osteosarcoma. Pediatric and Adolescent Osteosarcoma. Jaffe N,
Bruland SO and Bielack S: Springer; Boston, MA: pp. 3–13. 2010
|
|
2
|
Anderson ME: Recent advances in
osteosarcoma survival. Orthop Clin North Am. 47:283–292. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment methods and successful
cooperative approaches. J Clin Oncol. 33:30292015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lindsey BA, Markel JE and Kleinerman ES:
Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harrison DJ, Geller DS, Gill JD, Lewis VO
and Gorlick R: Existing and future treatments for osteosarcoma.
Expert Rev Anticancer Ther. 18:39–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duan Z, Gao Y, Shen J, Choy E, Cote G,
Harmon D, Bernstein K, Lozano-Calderon S, Mankin H and Hornicek FJ:
miR-15b modulates multidrug resistance in human osteosarcoma in
vitro and in vivo. Mol Oncol. 11:151–166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: Potential targets for microRNAs and osteosarcoma. Front
Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kulda V, Svaton M, Mukensnabl P, Hrda K,
Dvorak P, Houdek Z, Houfkova K, Vrzakova R, Babuska V, Pesek M, et
al: Predictive relevance of miR-34a, miR-224 and miR-342 in
patients with advanced squamous cell carcinoma of the lung
undergoing palliative chemotherapy. Oncol Lett. 15:592–599.
2018.PubMed/NCBI
|
|
10
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng L, Chen Y, Ma N and Chen X: NARRMDA:
Negative-aware and rating-based recommendation algorithm for
miRNA-disease association prediction. Mol Biosyst. 13:2650–2659.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grosswendt S and Rajewsky N: Essentials of
miRNA-dependent control of mRNA translation and decay, miRNA
targeting principles, and methods for target identification.
Essentials of Noncoding RNA in Neuroscience: Ontogenetics,
Plasticity of the Vertebrate Brain. Academic Press; London: pp.
19–38. 2017, View Article : Google Scholar
|
|
13
|
Chou CH, Chang NW, Shrestha S, Hsu SD, Lin
YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: miRTarBase
2016: Updates to the experimentally validated miRNA-target
interactions database. Nucleic Acids Res. 44:D239–D247. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang
S and Liu X: Long noncoding RNA MALAT1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 34:932–941. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sheng S, Xie L, Wu Y, Ding M, Zhang T and
Wang X: miR-144 inhibits growth and metastasis in colon cancer by
downregulating SMAD4. Biosci Rep. 39:BSR201818952019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown HK, Tellez-Gabriel M and Heymann D:
Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rickel K, Fang F and Tao J: Molecular
genetics of osteosarcoma. Bone. 102:69–79. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Yu X and Shen J: Long non-coding
RNAs: Emerging players in osteosarcoma. Tumour Biol. 37:2811–2816.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C and Lin J: Long noncoding RNA
ZEB1-AS1 activates ZEB1 as an oncogene of osteosarcoma by
epigenetic inheritance. Am J Transl Res. 8:40952016.PubMed/NCBI
|
|
21
|
Chen S, Li P, Li J, Wang Y, Du Y, Chen X,
Zang W, Wang H, Chu H, Zhao G, et al: miR-144 inhibits lung cancer
cell proliferation and induces apoptosis and autophagy by targeting
TIGAR. Cell Physiol Biochem. 35:997–1007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao M, Huang J, Gui K, Xiong M, Cai G, Xu
J, Wang K, Liu D, Zhang X and Yin W: The downregulation of miR-144
is associated with the growth and invasion of osteosarcoma cells
through the regulation of TAGLN expression. Int J Mol Med.
34:1565–1572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang
Z, Qiu F and Lin J: miR-144 downregulation increases bladder cancer
cell proliferation by targeting EZH2 and regulating Wnt signaling.
FEBS J. 280:4531–4538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao T, Li H, Hu Y, Ma D and Cai X: miR-144
suppresses the proliferation and metastasis of hepatocellular
carcinoma by targeting E2F3. Tumour Biol. 35:10759–10764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang W, Zhou X and Wei M: MicroRNA-144
suppresses osteosarcoma growth and metastasis by targeting ROCK1
and ROCK2. Oncotarget. 6:10297–10308. 2015.PubMed/NCBI
|
